About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Beam Therapeutics Inc. - Common Stock (NQ:BEAM)

25.73 -0.09 (-0.37%)
Streaming Delayed Price Updated: 11:27 AM EDT, Mar 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beam Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol ↗
Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with... 
Via Benzinga
News headline image
Expert Outlook: Beam Therapeutics Through The Eyes Of 4 Analysts ↗
 
Via Benzinga
News headline image
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Initiation of Phase 1/2 Trial of BEAM-302 in AATD Expected in First Half of 2024 
From Beam Therapeutics
Via GlobeNewswire
News headline image
MarketBeat Week in Review – 3/4 – 3/8
The market rally continues as the February Jobs Report reignited the soft landing talk, but momentum could stall if next week's inflation readings come in hot 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Navigating 4 Analyst Ratings For Beam Therapeutics ↗
 
Via Benzinga
News headline image
Recap: Beam Therapeutics Q4 Earnings ↗
 
Via Benzinga
News headline image
Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments
Beam Therapeutics stock is rising as the company begins to receive significant money from the multiple licensing deals it has in place 
Via MarketBeat
News headline image
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
From Beam Therapeutics
Via GlobeNewswire
News headline image
Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat ↗
Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81. 
Via Investor's Business Daily
News headline image
Beam Rockets 27%, Hitting A Year High, On Its Efforts To Take On Crispr's New Gene-Editing Drug ↗
Both companies are working on treatments for genetic disorders. 
Via Investor's Business Daily
News headline image
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
Via Benzinga
News headline image
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Beam Therapeutics Inc. (NASDAQ: BEAM) Leading the Way in Tuesday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
News headline image
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Beam Therapeutics Stock Shows Healthy Relative Strength Improvement ↗
In a welcome move, Beam Therapeutics stock saw its Relative Strength (RS) Rating rise from 67 to 76 on Friday. 
Via Investor's Business Daily
News headline image
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Cathie Wood Trims Nvidia, Shopify Stakes To Pump Whopping $40M Into Pinterest Despite Q4 Revenue Miss ↗
 
Via Benzinga
News headline image
3 Biotech Stocks to Buy on the Dip: February 2024 ↗
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities 
Via InvestorPlace
News headline image
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From Beam Therapeutics
Via GlobeNewswire
News headline image
Why Beam Therapeutics Stock Zoomed 17% Higher Today ↗
JPMorgan Chase becomes the latest institution in the company's bull pen. 
Via The Motley Fool
News headline image
2 gene editing stocks to keep on your 2024 watchlist
Gene therapy is receiving much of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) 
Via MarketBeat
News headline image
Bitcoin, Ethereum, Dogecoin Rise As Investors Weigh Spot ETF Impact: Analyst Says Scenario For King Crypto Is 'Rejection' At $46K And Then Correction To Below $40K ↗
Major cryptocurrencies on Tuesday evening posted some gains following a weekend characterized by 
Via Benzinga
Topics ETFs
News headline image
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market ↗
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry. 
Via InvestorPlace
News headline image
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street ↗
Analysts have high hopes for these three innovation companies in 2024. 
Via The Motley Fool
News headline image
3 Stocks to Buy in the Booming Field of Gene Editing ↗
As the promise of gene editing moves closer to being a reality, these gene editing stocks have the opportunity for long-term gains. 
Via InvestorPlace
News headline image
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
From Beam Therapeutics
Via GlobeNewswire
News headline image
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 ↗
Even if Wall Street is wrong about these stocks in the new year, Cathie Wood could still be right about them over the long run. 
Via The Motley Fool
News headline image
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 ↗
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
News headline image
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Beam Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.